To view a copy of this licence, visit About this article Cite this article Cong, R., Deng, C., Li, P
BREAKING NEWS APRIL 15, 2026 - In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500
It contains natural compounds like nimbidin, quercetin, and other polyphenols that give it antibacterial, antifungal, and anti-inflammatory activity
Effects of Qili Qiangxin Capsule on endothelial injury and energy metabolism in rats with pressure overload heart failure
Membrane Core-Specific Antimicrobial Action of Cathelicidin LL-37 Peptide Switches Between Pore and Nanofibre Formation
Robker RL, Hennebold JD, Russell DL